Welcome to BioArctic’s website. In order to optimize your use of our website we use cookies. If you want more information about our cookie policy, please read more here. By continuing, you agree to our use of cookies. Close English Svenska Home About us About us About BioArctic CEO Gunilla Osswald presents BioArctic Vision and mission Culture and values Objective and strategy Collaborations and partners Sustainability Code of Conduct Work environment Diversity Organization Senior management Board of directors Scientific advisory boards History Research and development Research and development Technology Pipeline Therapeutic Areas Neurodegenerative disorders Alzheimer´s disease Parkinson’s disease Therapeutic Areas Complete Spinal Cord Injury Other diseases Governance Governance Governance structure Corporate Governance Reports General Meeting General Meetings Nomination Committee Nomination Committees Board of Directors Composition of the board of directors Board Committees Work of the Board of Directors Senior management The tasks of the CEO and other senior executives Remuneration Internal audit and control Audit Articles of Association Investors Investors IPO The share Share capital development Dividend Ownership structure Analysts Financial reports Presentations Press releases News Calendar Subscribe Contact Media Media Press releases News Image bank Subscribe Contacts Career Contacts Contacts Office Investors Media Svenska Search for: Search Innovative treatments to help patients with central nervous disorders Read more about Complete Spinal Cord Injury Innovative treatments to help patients with central nervous disorders Read more about Parkinson’s disease Innovative treatments to help patients with central nervous system disorders Read more about Alzheimer’s disease Alzheimer’s disease Halting the disease progression would lead to great benefits to patients, families and caregivers. Read more Parkinson’s disease The medical need of treatments is high due to the lack of drugs affecting the underlying pathology. Read more Complete Spinal Cord Injury We are developing an innovative treatment that aims to improve the patients’ quality of life. Read more Press releases July 25, 2018BioArctic announces detailed results of the BAN2401 Phase 2b study in early Alzheimer’s disease presented at AAIC 2018 July 18, 2018BioArctic: Late breaking Phase 2b study results of BAN2401 in Alzheimer’s disease will be webcast live from AAIC 2018 by Eisai July 10, 2018BioArctic receives regulatory approval in Finland for a clinical study in patients with Complete Spinal Cord Injury Archive Interim Report January – March 2018 BioArctic AB published the company’s Interim Report January – March 2018 on Thursday, April 26. Report Presentation Webcast Read the report Calendar August 23, 2018Interim Report January – June 2018 November 8, 2018Interim Report January – September 2018 All events Proud partner of: About us About BioArctic CEO Gunilla Osswald presents BioArctic Vision and mission Culture and values Objective and strategy Collaborations and partners Sustainability Organization History Research and development Technology Pipeline Therapeutic Areas Governance Governance structure Corporate Governance Reports General Meeting Nomination Committee Board of Directors Senior management Remuneration Internal audit and control Audit Articles of Association Investors IPO The share Financial reports Presentations Press releases News Calendar Subscribe Contact Media Press releases News Image bank Subscribe Contacts Career Career Contacts Office Investors Media BioArctic AB, Warfvinges väg 35, SE-112 51 Stockholm, Sweden. Phone: +46 8 695 69 30. E-mail: info@bioarctic.se. Registration number: 556601-2679. © 2018 BioArctic AB – All rights reserved About Cookies Processing of personal data